Organon keeps pedal to the metal, buying up Forendo in 3rd deal since spinning out of Merck Genentech, Novome team up to study seaweed-controlled oral cell therapies in IBD Vaxxinity, hoping to turn bodies into their own drug factories, makes a subdued Wall Street debut Sponsored: A New Reference Model for Clinical Trial Recruitment, Enrollment and Retention Success Shasqi snatches $50M for chemotherapy-boosting treatments thanks to Arcus, NGM execs Acrivon Therapeutics secures $100M to give Eli Lilly cancer drug another try, fund 2 solid tumor candidates Eli Lilly touts long-term safety data for Olumiant amid classwide scrutiny on JAK meds Startup Regulonix pursues non-opioid pain drug that indirectly blocks a key ion channel Taking a bite out of Big Tech: Outgoing J&J CEO Gorsky takes health tech talents to Apple Express Scripts launches option for employers to cover over-the-counter COVID-19 tests Featured Story | By Nick Paul Taylor The rat-a-tat-tat pace of dealmaking at Merck spinout Organon continues. Having identified more than 140 clinical-phase assets in its wheelhouse, Organon has pulled the trigger on its third deal in six months by agreeing to buy Forendo Pharma for an initial $75 million. read more |
| |
|---|
|
Top Stories By Nick Paul Taylor Are seaweed-controlled oral cell therapies the future of inflammatory bowel disease therapy? That is the question posed by the latest deal from Genentech, which is teaming up with Novome Biotechnologies to study a novel approach to the indication. read more By Ben Adams Immunotherapeutic vaccine developer Vaxxinity, with an eye on COVID and some serious CNS diseases, has pulled off a fairly small IPO. read more Sponsored by: IPM.ai Rare diseases demand a modern recruitment approach grounded in uncovering the ideal, medically-eligible patient population with the highest propensity for study enrollment and retention. read more By Emmy Lucas Shasqi has collected $50 million in a series B financing to fuel the path through the clinic. The funding round was driven by a cohort of private investors including Arcus Biosciences President Juan Jaen, Ph.D., and Bill Rieflin, executive chairman of the board at NGM Biopharmaceuticals. read more By Kyle LaHucik Prexasertib has been investigated in nearly 20 clinical studies since being discovered by Array in the 1990's, but Eli Lilly decided to part ways with it in 2019. Now, Acrivon Therapeutics has $100 million in funding to give the drug another shot at potentially treating solid cancers through an equity and licensing agreement with Lilly. read more By Angus Liu Eli Lilly’s Olumiant has been dragged into a classwide safety review of JAK medicines that originated from Pfizer’s Xeljanz. Hoping to convince doctors that its offering doesn’t share the problems at the same magnitude, the Indianapolis pharma is turning to long-term data. read more By Angus Liu The NaV1.7 ion channel is expressed in some neurons and plays a critical role in sensing pain, but suppressing it head-on has proven tricky. A drug that blocks the channel through two related proteins relieved pain in several animal models, a University of Arizona team reported, and Regulonix has licensed it for development. read more By Andrea Park As Apple continues to accelerate its push into healthcare, the Big Tech company will have a seasoned veteran of the health tech world on its side. read more By Paige Minemyer Plans can set the copayment for the test at either a discounted rate or a $0 copay, Express Scripts said. read more Resources Sponsored by: Medable, Inc. Find out how to improve clinical protocol adherence, and thus patient outcomes, by 15%+ with Medable’s latest White Paper. Sponsored by: IQVIA Learn how to elevate your omnichannel marketing strategy with Next Best - a combination of data and analytics, deployed to facilitate decision making. Sponsored by: Catalent Biologics Ypsomed and Catalent Biologics experts discuss strategies for integrated PFS manufacturing and auto-injector assembly to accelerate timelines and more in this webinar. Sponsored by: Catalent Biologics Learn how formulation development for a PFS affects manufacturing to drive the industry toward optimizing delivery of injectable products and, ultimately, improving patient care. Sponsored by: Blue Matter Consulting Paper describing how the chronic insomnia market offers big lessons for any biopharma company thinking about getting into digital therapeutics in any therapeutic area. Sponsored by: TransPerfect Life Sciences Every detail is important when selecting a new eCOA solution; learn more about the current eCOA landscape, best practices, and crucial considerations for successful eCOA solution deployment in this white paper. Sponsored by: Informa Pharma Intelligence and Oracle Health Sciences New market research provides valuable insight into the impact of adaptations made in clinical trials during the pandemic. Sponsored by: Thermo Fisher Scientific Learn how to develop a high-performing supply chain for cGMP chemicals used throughout your biologics workflow. Download the free whitepaper from Thermo Fisher Scientific Sponsored by: Drexel University Online Drexel University’s online graduate programs in biomedicine, clinical research, drug discovery, and molecular medicine were developed with working professionals in mind, providing you with the education, practical skills, and competitive edge you need to be successful in your career. Learn more. Sponsored by: Box Read Get to Know Cloud Content Management for Life Sciences and learn how to eliminate silos across all workflows, from R&D to commercialization. Pharma Meeting Pros Summit November 3-4, 2021 | Atlantic City, NJ & Virtual Fierce Diversity, Equity & Inclusion Summit November 9–10, 2021 | Virtual Event Drug Development Boot Camp® 2021 VIRTUAL November 17-18, 2021 Learn impact of pricing, competitive assessment, epidemiology November 17-18, 2021 | Live & Online Fierce New Product Planning Summit December 1-2, 2021 | Boston, MA Fierce Launch Readiness for Medical Affairs & Communications Teams December 1-2, 2021 | Boston, MA Learn how therapeutics are successfully launched and commercialized December 1-2, 2021 | Live & Online 2nd Annual Symposium on Translational Medicine and Biomanufacturing December 2—3, 2021 Fierce Virtual Clinical Trials Summit December 6-7, 2021 | Philadelphia, PA Fierce JPM Week 2022 January 11, 2022 | San Francisco, CA
January 18-20, 2022 | Virtual Event Virtual European Healthcare Compliance Certificate Program January 24-28, 2022 Fierce Pharma Drug Safety Summit February 8-9, 2022 | Location TBD Fierce Business Development and Licensing Summit March 15, 2022 | San Francisco, CA Fierce Medical Affairs Strategic Summit (MASS) East April 2022 | New Jersey Fierce Trial Master File Summit May 2022 | Location TBD Fierce Promotional Review Committee Compliance and Best Practices Summit April 2022 | New Jersey Fierce Digital Pharma Innovation Week June 2022 | Virtual Event Fierce Pharma PR & Communications Summit July 2022 | Location TBD (NYC Metro Area) Fierce Biotech Forum October 2022 | Location TBD | 